Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Apontis Pharma AG's annualized net income for the quarter that ended in Jun. 2025 was €1.21 Mil. Apontis Pharma AG's average shareholder tangible equity for the quarter that ended in Jun. 2025 was €12.96 Mil. Therefore, Apontis Pharma AG's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2025 was 9.32%.
The historical rank and industry rank for Apontis Pharma AG's Return-on-Tangible-Equity or its related term are showing as below:
FRA:APPH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -59.27 Med: -2.17 Max: 10.45
Current: 4.93
During the past 7 years, Apontis Pharma AG's highest Return-on-Tangible-Equity was 10.45%. The lowest was -59.27%. And the median was -2.17%.
FRA:APPH's Return-on-Tangible-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.9
vs FRA:APPH: 4.93
Apontis Pharma AG (FRA:APPH) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Apontis Pharma AG Return-on-Tangible-Equity Related Terms
Apontis Pharma AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Apontis Pharma AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:APPH vs ZTS, UTHR, NBIX: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Jun. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.32% mean?
Apontis Pharma AG (FRA:APPH) has a Return-on-Tangible-Equity of 9.32% as of Jun. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Apontis Pharma AG and its competitors.
Is Apontis Pharma AG's Return-on-Tangible-Equity too high?
Apontis Pharma AG's current Return-on-Tangible-Equity is 9.32%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Apontis Pharma AG's value of 9.32% is 18% above this industry median. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's Return-on-Tangible-Equity compare to ZTS and UTHR?
Apontis Pharma AG's Return-on-Tangible-Equity of 9.32% can be compared against companies in the Drug Manufacturers industry. The industry median Return-on-Tangible-Equity is 7.90. Apontis Pharma AG's value of 9.32% is 18% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apontis Pharma AG's current Return-on-Tangible-Equity of 9.32% is 18% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Apontis Pharma AG and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apontis Pharma AG's current Return-on-Tangible-Equity is 9.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current Return-on-Tangible-Equity of 9.32%. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current Return-on-Tangible-Equity is 9.32% and 18% above the Drug Manufacturers industry median of 7.90. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current Return-on-Tangible-Equity is 9.32% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?
Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued.
The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.
Key valuation signals for FRA:APPH:
Return-on-Tangible-Equity: 9.32%
GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
Industry Position: 18% above the Drug Manufacturers median
No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score
Get the complete analysis for FRA:APPH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APPH has been successfully added to your 
